Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

193.72 +0.50 (+0.26%)
Official Closing Price Updated: 7:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings
 
Via Benzinga
Wall Street's Earnings Momentum Fades, Market Dips Amidst Trade Tensions
Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which... 
Via MarketMinute
Topics Economy Supply Chain World Trade
Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst
Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing fair valuation. 
Via Benzinga
2 Dividend Stocks I'm Very Thankful I Owned This Year
I don't intend to sell my shares of these companies anytime soon. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Johnson & Johnson To Separate Its Orthopedic Business
Via Stocktwits
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
Via Stocktwits
Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off
Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock. 
Via MarketBeat
New Jersey Rep. Thomas Kean Sold Up to $215K Worth of Franklin Resources Stock
 
Via Benzinga
2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 41% in 12 Months, According to Select Wall Street Analysts
Juicy dividends are only part of the attraction with these beaten-down stocks. 
Via The Motley Fool
Topics Government
This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy
Johnson & Johnson has a very healthy financial profile and growth prospects. 
Via The Motley Fool
Topics Bonds
Powell Calms the Markets While Trade Tensions Keep Investors on Edge
A dovish tone from Fed Chair Jerome Powell helped Wall Street recover from early losses, but U.S.–China tensions under President Trump’s renewed tariff threats kept sentiment fragile. Strong bank... 
Via Chartmill
Topics Economy Government World Trade
AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
Looking At Johnson & Johnson's Recent Unusual Options Activity
 
Via Benzinga
The Gathering Storm: AI Overbuilding, Trade Wars, and National Debt Fuel Market Crash Fears
As of October 14, 2025, a palpable sense of unease permeates global financial markets, with a growing chorus of analysts and institutions warning of a potential market crash. The prevailing sentiment... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Johnson & Johnson To Spin Off Orthopedics Unit After Raising 2025 Sales Forecast
Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings. 
Via Talk Markets
S&P Drug Titan J&J Dips After Announcing A Surprise Spinoff
The news comes alongside a third-quarter beat and sales guidance hike. 
Via Investor's Business Daily
Topics Stocks
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes. 
Via Benzinga
Johnson & Johnson (NYSE:JNJ) Beats Q3 2025 Estimates and Raises Full-Year Sales Outlook
Johnson & Johnson (JNJ) beat Q3 2025 earnings estimates, raised its full-year sales outlook, and announced a planned spin-off of its Orthopedics business. 
Via Chartmill
Stock Market Today: S&P 500, Nasdaq Futures Tumble Ahead Of Big Bank Earnings—Goldman Sachs, JPMorgan, Citigroup In Focus
U.S. stock futures declined on Tuesday following Monday’s reversal rally. Futures of major benchmark indices were lower. 
Via Benzinga
Topics Stocks
Earnings Scheduled For October 14, 2025
 
Via Benzinga
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
Via Stocktwits
Topics Government World Trade
Goldman Sachs, JPMorgan Chase And 3 Stocks To Watch Heading Into Tuesday
US stock futures lower, focus on Goldman Sachs, JPMorgan, Polaris, Johnson & Johnson, and Citigroup earnings. 
Via Benzinga
Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing
Via The Motley Fool
Topics Regulatory Compliance
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035. 
Via Benzinga
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst. 
Via Benzinga
Dividend Powerhouses: Should You Grab These 3 Before Earnings Drop?
As the Q3 2025 earnings season hits full stride, a critical question looms for income-focused investors: are "dividend powerhouses" still a safe haven, and should they be considered before their... 
Via MarketMinute
Topics Bonds Earnings Economy
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit. 
Via Benzinga
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early... 
Via MarketMinute
Topics Economy Government Stocks
A Peek at Johnson & Johnson's Future Earnings
 
Via Benzinga
Retail Investors' Top Stocks With Earnings This Week: Fastenal, ASML, TSMC And More
Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this week. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.